# A Safety and Efficacy Study Comparing the Combination Treatments of Verteporfin Therapy Plus One of Two Different Doses of Intravitreal Triamcinolone Acetonide and the Verteporfin Therapy Plus Intravitreal Pegaptanib

> **NCT00242580** · PHASE3 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 111 (actual)

## Conditions studied

- Macular Degeneration
- Choroidal Neovascularization

## Interventions

- **DRUG:** Verteporfin photodynamic therapy
- **DRUG:** Pegaptanib
- **DRUG:** Triamcinolone acetonide

## Key facts

- **NCT ID:** NCT00242580
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-09
- **Primary completion:** 2008-01
- **Final completion:** —
- **Target enrollment:** 111 (ACTUAL)
- **Last updated:** 2016-03-31

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00242580

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00242580, "A Safety and Efficacy Study Comparing the Combination Treatments of Verteporfin Therapy Plus One of Two Different Doses of Intravitreal Triamcinolone Acetonide and the Verteporfin Therapy Plus Intravitreal Pegaptanib". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT00242580. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*